enGene adds Lota Zoth to its Board of Directors

– CANADA, St-Laurent –  enGene Holdings Inc. (Nasdaq: ENGN), a clinical-stage genetic medicines company whose lead program is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer, today announced the appointment of Lota Zoth to its Board of Directors.…